Raf kinase and VEGFR-2 inhibitor. Inhibits c-Raf, wild type B-Raf and mutant B-Raf (V600E). Cytotoxic in certain melanoma cells lines. Effects enhanced by protein kinase D3 inhibition, preventing reactivation of MAPK signaling and increasing caspase activity. Orally bioavailable.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 518.41. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.93 mL||9.64 mL||19.29 mL|
|5 mM||0.39 mL||1.93 mL||3.86 mL|
|10 mM||0.19 mL||0.96 mL||1.93 mL|
|50 mM||0.04 mL||0.19 mL||0.39 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Chen et al (2011) Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling. Cancer Res. 71 4280 PMID: 1527556
If you know of a relevant reference for RAF 265, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: RAF265 Raf kinases inhibitors inhibits B-Raf c-Raf VEGFR2 vascular endothelial growth factor cytotoxic MAPK CHIR 265 Raf Kinase
Citations for RAF 265
Citations are publications that use Tocris products.
Currently there are no citations for RAF 265. Do you know of a great paper that uses RAF 265 from Tocris? If so please let us know.